GSK’s Shin­grix leader Guil­laume Pfe­fer has jumped on board Flag­ship to helm a biotech hy­brid as Afeyan’s lat­est CEO-part­ner

Af­ter spend­ing 4 years in a se­nior post with Glax­o­SmithK­line’s star team po­si­tion­ing Shin­grix for a block­buster ap­proval, Guil­laume Pfe­fer is head­ed back to the biotech world — in style.

Pfe­fer has signed on to join Noubar Afeyan’s busy group of part­ners at Flag­ship, and he’s tak­ing the helm of an up­start — which to­day is be­ing merged with an­oth­er Flag­ship start­up — with some grand plans of its own. The an­nounce­ment this morn­ing notes that Pfe­fer will run Kin­tai Ther­a­peu­tics, one of the grads of the Flag­ship labs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.